Clinical Trial Update: Arsenic Trioxide for Structural p53 Mutations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating arsenic trioxide for cancers with structural p53 mutations (refractory/intractable cancers).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Cancer with P53 Mutations
• Intractable Cancer

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Arsenic Trioxide, p53 Mutations | Phase 2 | Status: UNKNOWN